Ambrx Biopharma — Investor Day (February 2023)
19 slides from Ambrx Biopharma's investor day presentation, Feb 24, 2023

Slide 1: Analyst and Investor Day February 24, 2023
Analyst and Investor Day February 24, 2023 Exhibit 99.1

Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements contained in this presentation, other than statements of historical fact, are "forward-looking" statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such

Slide 3: ARX788 Anti-HER2 ADC for Patients with Post-Enhertu HER2+ Metastatic Breast Cancer
ARX788 Anti-HER2 ADC for Patients with Post-Enhertu HER2+ Metastatic Breast

Slide 4: Efficacy Signal Seen in Post-Enhertu Patients with ARX788
Efficacy Signal Seen in Post-Enhertu Patients with ARX788 In October 2022, Ambrx strategically reprioritized its pipeline and paused further internal development of ARX-788, while seeking partnership ACE-Breast-03 study - Clinical study evaluating ARX788 in metastatic HER+ breast cancer (mBC) post-E

Slide 5: Enhertu changed the breast cancer ADC landscape, but many patients progress
Enhertu changed the breast cancer ADC landscape, but 24.2% of patients on Enhertu progress within 12 months No post-Enhertu data supporting the effectiveness of Kadycla and/or Tukysa potentially creates a new large market opportunity with no standard of care

Slide 6: Post-Enhertu Market Could be a Billion Dollar Opportunity
Post-Enhertu Market Could be a Billion Dollar Opportunity Estimated Drug treated patients in 3L+ (ie, 3L or later) HER2+ BC: 10,000 to > 14,000, depending on source 9,800 drug-treated patients per DRG, March 2020 report; estimate for 2028, 7MM >14,000 patients per HER2 competitors Roche and AstraZen

Slide 7: Rationale for Continuing Evaluation of ARX788 in post-Enhertu mBC Patients
Rationale for Continuing Evaluation of ARX788 in post-Enhertu mBC Patients Preliminary data from paused studies provide rationale for anti-tumor activity in post-Enhertu and post Kadcyla, as well as HER2 low patients Completed study (ACE-Breast-01) demonstrates robust response rate in the HER2 metas

Slide 8: Planned Phase 2 Study of Patients Post-Enhertu
Planned Phase 2 Study of Approximately 30 Patients Post-Enhertu Amend existing ACE-Breast-03 protocol and submit to FDA (approx. 3-month process) Leverage existing / open clinical trial sites in ACE-Breast-03 to enable quicker study start Patients with no more than 3 prior lines of therapy and recen

Slide 9: ARX517 Anti-PSMA ADC for Prostate and Other Cancers
ARX517 Anti-PSMA ADC for Prostate and Other Cancers

Slide 10: ARX517 - APEX-01 Phase 1 Trial Design
ARX517 - APEX-01 Phase 1 Trial Design Dose Expansion in metastatic-castration resistant prostate cancer (mCRPC) (Up to 40 Subjects) MTD or RP2D Expansion 0.32 mg/kg C1 0.64 mg/kg C2 1.07 mg/kg C3 1.4 mg/kg C4 1.7 mg/kg C5 2.0 mg/kg C6 2.4 mg/kg C7 Objectives Primary Safety Tolerability MTD RP2D Seco

Slide 11: The Case for ARX517 in mCRPC
The Case for ARX517 in mCRPC PSMA is highly expressed (89%) in metastatic castration resistant prostate cancer (mCRPC), as well as neovasculature of various solid tumors PSMA is a clinically validated target and an established market for mCRPC Pluvicto has validated the PMSA as an effective prostate

Slide 12: Appendix
Appendix

Slide 13: ARX788 – A Novel Anti-HER2 Antibody–Drug Conjugate (ADC)
ARX788 – A Novel Anti-HER2 Antibody–Drug Conjugate (ADC) Binding domain Site specific conjugation Light Chain Heavy Chain ARX788 ARX788 is novel ADC comprised of an anti-HER2 mAb and a potent tubulin inhibitor payload AS269 that is site-specifically conjugated to the antibody via a synthetic amino a

Slide 14: ACE-Breast-01 results with ARX788
ACE-Breast-01 69 patients were enrolled in China, ORR was 65.5%, the DCR was 100% and the median progression-free survival was 17.02 months. ARX788 was well tolerated with most adverse events being grade 1 or 2 and were manageable, low systemic toxicity was observed, no DLT or drug-related deaths oc

Slide 15: Summary of ARX788 Safety Data (All Cohorts)
ARX788 (All Treated Population) Number of patients (%) ACE-Breast-01 (N=69) ACE-Pan-Tumor-01 (N=67) ACE-Gastric-01 (N=30) All AEs (regardless of causality) 69 (100%) 61 (91.0%) 29 (96.7%) Drug-related AEs (any grade) 67 (97.1%) 48 (71.6%) 28 (93.3%) All AEs ≥ Grade 3 and Grade 4 AEs 16 (23.2%) 23 (

Slide 16: Key Takeaways: ACE-Breast-03 post T-DM1
Key Takeaways ARX788 provided clinical benefit to patients previously treated with T-DM1 who had disease progression 4/7 patients also previously received HER2 TKI treatment Confirmed objective response rate (ORR) was 57.1% (4/7 pts) and an unconfirmed ORR of 71.4% (5/7 pts) Disease control rate (DC

Slide 17: ARX788 Has Competitive Activity in the HER2 ADC Landscape
Data from ACE-Breast-01 Demonstrates that ARX788 Has Competitive Activity in the HER2 ADC Landscape FOR ILLUSTRAVE PURPOSES ONLY – Not a head-to-head analysis *ACE-Breast-01 conducted in China by Ambrx’s partner, NovoCodex Biologics **SeaGen acquired rights for RC48 for $200M as well as $2.4B in mil

Slide 18: ARX788 Potential Mechanisms to Overcome Enhertu Resistance
ARX788 Potential Mechanisms to Overcome Enhertu Resistance Cytotoxicity of ARX788 has a different MOA than Kadcyla (DM1) or Enhertu (DXd) ARX788 potentially maximizes the delivery and efficiency of the cytotoxic payload (AS269) into HER2-expressing tumor cells ARX788 potentially overcomes payload re

Slide 19: ARX517 is the only ADC targeting PSMA in prostate cancer
ARX517 is the only ADC targeting PSMA in prostate cancer Binding domain Site specific conjugation Light Chain Heavy Chain ARX517 Potential to Become First-in-Class & Best-in-Class PSMA-ADC Fully humanized anti-PSMA monoclonal antibody (mAb) produced in CHO cells with site-specific incorporation of a
Source: SEC EDGAR · 8-K filed Feb 24, 2023



